In California, biobased chemical producer Amyris says it is set to submit regulatory filings for an undisclosed health and nutrition ingredient.
The nature of the ingredient is not specified due to partner requirements, Amyris says, but market entry is expected in the first half of 2020.
“Our ability to speed time to market at lower cost and with better purity is why the leading companies continue to rely on Amyris,” says John Melo, Amyris President and CEO, in a press statement. The undisclosed ingredient serves a “large market,” he adds. “We are very excited about the continued potential of synthetic biology to deliver a significant impact in making the world healthier one molecule at a time and our transition to profitable growth.”
In the health and nutrition sector, Amyris has already scaled up production of artemisinin, vitamin E and, most recently, Reb M.